Laros Mint (Amylmetacresol, 2,4 Dichlorobenzyl Alcohol, Lidocaine Hydrochloride)

• Laros Mint, containing antiseptic and local anesthetic agents, is used to relieve symptoms in the upper respiratory tract.
• Sore throat: provides symptomatic relief and reduces microbial presence in the throat.
• Mouth and throat irritation: soothes discomfort and helps control local infection.
• Throat discomfort: eases pain and irritation associated with minor pharyngeal inflammation.

• Amylmetacresol and 2,4‑dichlorobenzyl alcohol act as broad‑spectrum antiseptics by disrupting microbial cell membranes, leading to loss of viability. Lidocaine hydrochloride produces local anaesthesia by reversibly blocking voltage‑gated sodium channels in peripheral nerves, preventing depolarisation and transmission of pain signals. The combined actions provide antimicrobial activity together with rapid symptomatic relief when the lozenge dissolves in the oral cavity.

Laros Mint may cause adverse reactions, most of which are mild and transient.

Common Side Effects

• Altered taste: temporary metallic or sweet taste in the mouth.
• Mild oral numbness: brief sensation of numbness on the tongue or palate.
• Mild throat irritation: slight burning or itching after lozenge dissolution.
• Dry mouth: temporary reduction in salivary flow.
• Nausea: occasional mild upset stomach.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Anaphylaxis: severe, life‑threatening hypersensitivity requiring emergency care.
• Severe oral mucosal ulceration: persistent ulcer or erosion in the mouth.
• Cardiac arrhythmia: irregular heartbeat associated with systemic lidocaine absorption (rare).

• Before using Laros Mint, consider the following precautions to ensure safe use.
• Pregnancy: consult a healthcare professional as safety has not been established.
• Breastfeeding: use with caution and seek medical advice.
• Allergy: avoid if known hypersensitivity to amylmetacresol, 2,4‑dichlorobenzyl alcohol or lidocaine.
• Age restriction: not recommended for children under six years of age.
• Drug interactions: discuss all concurrent medications with a physician.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Laros Mint can interact with other medicines; awareness of potential interactions helps minimise risk.

Major Interactions (Avoid)

• Concurrent use of other topical anesthetics: may increase systemic lidocaine exposure.
• Co‑administration with high‑dose CYP3A4 inhibitors (e.g., ketoconazole): can raise lidocaine plasma levels.
• Use with other antiseptic lozenges containing similar agents: may cause additive mucosal irritation.

Moderate Interactions (Monitor Closely)

• Alcohol consumption: may enhance lidocaine absorption and increase sedation.
• Medications that lower seizure threshold (e.g., bupropion): monitor for neurological symptoms.
• Drugs affecting hepatic metabolism (e.g., cimetidine): may modestly alter lidocaine clearance.